nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Acute Heart Failure Presentation to the Emergency Department
|
Rao, Aarti |
|
|
12 |
1 |
p. 229-231 |
artikel |
2 |
Addressing United States Heart Transplant Allocation in an Era of Rapid Innovation ∗
|
Truby, Lauren K. |
|
|
12 |
1 |
p. 216-221 |
artikel |
3 |
30- and 60-Day Readmission Rates for Children With Heart Failure in the United States
|
Amdani, Shahnawaz |
|
|
12 |
1 |
p. 83-96 |
artikel |
4 |
A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor
|
Zile, Michael R. |
|
|
12 |
1 |
p. 182-196 |
artikel |
5 |
Cardiopulmonary Performance Among Heart Failure Patients Before and After Left Ventricular Assist Device Implantation
|
Buchanan, Cole |
|
|
12 |
1 |
p. 117-129 |
artikel |
6 |
Combined Inhibition of Phosphodiesterase-5 and -9 in Experimental Heart Failure
|
Rademaker, Miriam T. |
|
|
12 |
1 |
p. 100-113 |
artikel |
7 |
Editorial Board
|
|
|
|
12 |
1 |
p. i-v |
artikel |
8 |
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF
|
Dhingra, Nitish K. |
|
|
12 |
1 |
p. 35-46 |
artikel |
9 |
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy
|
Coats, Caroline J. |
|
|
12 |
1 |
p. 199-215 |
artikel |
10 |
Full Issue PDF
|
|
|
|
12 |
1 |
p. e1-e242 |
artikel |
11 |
General Information
|
|
|
|
12 |
1 |
p. vii-viii |
artikel |
12 |
Innovative Dual Targeting of the Phosphodiesterase Family and Cyclic GMP Pathway in Heart Failure ∗
|
Burnett Jr., John C. |
|
|
12 |
1 |
p. 114-116 |
artikel |
13 |
Is There a Role for Risk Scores in the Management of Heart Failure? ∗
|
Abou Alaiwi, Sarah |
|
|
12 |
1 |
p. 197-198 |
artikel |
14 |
Managing Obesity in Heart Failure
|
Harrington, Josephine |
|
|
12 |
1 |
p. 28-34 |
artikel |
15 |
Mavacamten
|
Ammirati, Enrico |
|
|
12 |
1 |
p. 178-181 |
artikel |
16 |
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
|
Rader, Florian |
|
|
12 |
1 |
p. 164-177 |
artikel |
17 |
1+2 Might Be >2
|
Pitt, Bertram |
|
|
12 |
1 |
p. 222-225 |
artikel |
18 |
Natriuretic Peptide Normative Levels and Deficiency
|
Shetty, Naman S. |
|
|
12 |
1 |
p. 50-63 |
artikel |
19 |
NT-proBNP Concentrations in the Community
|
Ibrahim, Nasrien E. |
|
|
12 |
1 |
p. 64-66 |
artikel |
20 |
Officers Page
|
|
|
|
12 |
1 |
p. vi |
artikel |
21 |
Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies
|
Jansen, Mark |
|
|
12 |
1 |
p. 134-147 |
artikel |
22 |
Physical Activity Trajectories Preceding Incident Heart Failure
|
Hughes, Andrew M. |
|
|
12 |
1 |
p. 232-234 |
artikel |
23 |
Reducing Pediatric Heart Failure Readmissions
|
Wright, Lydia K. |
|
|
12 |
1 |
p. 97-99 |
artikel |
24 |
Rewarding Site-Based Research
|
Dimond, Matthew G. |
|
|
12 |
1 |
p. 226-228 |
artikel |
25 |
SGLT2 Inhibitors and Diuresis
|
Vardeny, Orly |
|
|
12 |
1 |
p. 47-49 |
artikel |
26 |
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity
|
Oren, Ohad |
|
|
12 |
1 |
p. 79-82 |
artikel |
27 |
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy–Related Cardiac Dysfunction
|
Avula, Vennela |
|
|
12 |
1 |
p. 67-78 |
artikel |
28 |
Shedding Light on the Darkness of MYH7 Cardiomyopathies ∗
|
Kantor, Paul F. |
|
|
12 |
1 |
p. 148-149 |
artikel |
29 |
Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies
|
Lala, Anuradha |
|
|
12 |
1 |
p. 1-15 |
artikel |
30 |
Tafamidis Efficacy Among Octogenarian Patients in the Phase 3 ATTR-ACT and Ongoing Long-Term Extension Study
|
Garcia-Pavia, Pablo |
|
|
12 |
1 |
p. 150-160 |
artikel |
31 |
Tafamidis in Octogenarians
|
Mitchell, Joshua D. |
|
|
12 |
1 |
p. 161-163 |
artikel |
32 |
The Need for Speed
|
Sauer, Andrew J. |
|
|
12 |
1 |
p. 130-133 |
artikel |
33 |
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices
|
Rodenas-Alesina, Eduard |
|
|
12 |
1 |
p. 16-27 |
artikel |